---
schema_version: "secwatch.filing_event.v1"
accession: "0001013762-24-002122"
form_type: "8-K"
ticker: "ACOG"
cik: "0001655923"
company_name: "Alpha Cognition Inc."
filed_at: "2024-07-29T23:59:59+00:00"
generated_at: "2026-05-31T15:44:22.047034+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Alpha Cognition gets FDA approval for ZUNVEYL to treat mild-to-moderate Alzheimer's

## Summary
- FDA approved ZUNVEYL (benzgalantamine) for mild-to-moderate Alzheimer's disease; second oral AD therapy approved this decade.
- GI adverse events under 2% and no insomnia observed in bioequivalence studies, designed to bypass GI absorption.
- Commercial availability planned in pharmacies nationwide starting Q1 2025.
- CEO Michael McFadden called approval a major breakthrough; company targets tolerability issues leading to 55% discontinuation rate.

## SEC filing metadata
- accession: 0001013762-24-002122
- form_type: 8-K
- ticker: ACOG
- cik: 0001655923
- company_name: Alpha Cognition Inc.
- filed_at: 2024-07-29T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655923/000101376224002122/0001013762-24-002122-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655923/000101376224002122/ea0210215-8k_alpha.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001013762-24-002122
- JSON: https://secwatch.observer/filing/0001013762-24-002122.json
- Plain text: https://secwatch.observer/filing/0001013762-24-002122.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.